These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14571691)

  • 1. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
    Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
    Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
    Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
    Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
    Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
    Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
    J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
    Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
    J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
    Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):15-21. PubMed ID: 18635408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
    Eiseman JL; Lan J; Lagattuta TF; Hamburger DR; Joseph E; Covey JM; Egorin MJ
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):21-32. PubMed ID: 15338192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
    Guo W; Reigan P; Siegel D; Ross D
    Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
    Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
    Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
    Roh JL; Kim EH; Park HB; Park JY
    Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.